Order Article Reprints

Candoni A, Chiusolo P, Lazzarotto D, Sartor C, Dargenio M, Chiaretti S, Skert C, Giglio F, Trappolini S, Fracchiolla NS, et al. Ponatinib as a Prophylactic or Pre-Emptive Strategy to Prevent Cytological Relapse after Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Transplanted in Complete Cytological Remission. Cancers. 2024; 16(11):2108. https://doi.org/10.3390/cancers16112108

Candoni, Anna, Patrizia Chiusolo, Davide Lazzarotto, Chiara Sartor, Michelina Dargenio, Sabina Chiaretti, Cristina Skert, Fabio Giglio, Silvia Trappolini, Nicola Stefano Fracchiolla, and et al. 2024. "Ponatinib as a Prophylactic or Pre-Emptive Strategy to Prevent Cytological Relapse after Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Transplanted in Complete Cytological Remission" Cancers 16, no. 11: 2108. https://doi.org/10.3390/cancers16112108

Candoni, A., Chiusolo, P., Lazzarotto, D., Sartor, C., Dargenio, M., Chiaretti, S., Skert, C., Giglio, F., Trappolini, S., Fracchiolla, N. S., Medici, S., Bresciani, P., Cuoghi, A., & Papayannidis, C. (2024). Ponatinib as a Prophylactic or Pre-Emptive Strategy to Prevent Cytological Relapse after Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Transplanted in Complete Cytological Remission. Cancers, 16(11), 2108. https://doi.org/10.3390/cancers16112108